{"prompt": "['Heart failure (NYHA class III or IV)', 'Anaphylaxis associated any of the study drugs', 'Patients who experience disease recurrence will be withdrawn from study treatment and', 'treated as clinically indicated, according to local clinical practice', 'The primary reason for study treatment discontinuation should be documented on the', 'appropriate eCRF. Patients who discontinue study treatment prematurely will not be', 'replaced.', 'Patients who discontinue study treatment prematurely will return to the clinic for an End of', 'Treatment Visit 28 days ( 7 days) of the administration of the last dose of study drug and', 'will continue in the Follow-up Period (see Appendix 1 for additional details). Anti-cancer', 'treatment for patients who have prematurely discontinued study treatment is at the discretion', 'of the investigator as clinically indicated.', '4.6.2', 'Patient Discontinuation from Study', 'Patients have the right to voluntarily withdraw from the study at any time for any reason. In', 'addition, the investigator has the right to withdraw a patient from the study at any time.', 'Reasons for withdrawal from the study may include, but are not limited to, the following:', 'Patient withdrawal of consent', 'Study termination or site closure', 'Patient non-compliance, defined as failure to comply with protocol requirements as', 'determined by the investigator or Sponsor', 'Every effort should be made to obtain information on patients who withdraw from the study', 'but have not withdrawn consent. The primary reason for withdrawal from the study should', 'be documented on the appropriate eCRF. If a patient requests to be withdrawn from the', 'study, this request must be documented in the source documents and signed by the', 'investigator. Patients who withdraw from the study will not be replaced.', 'If a patient withdraws from the study, the study staff may use a public information source to', 'obtain information about survival status.', '4.6.3', 'Study Discontinuation', 'The Sponsor has the right to terminate this study at any time. Reasons for terminating the', 'study may include, but are not limited to, the following:', 'The incidence or severity of AEs in this or other studies indicates a potential health', 'hazard to patients', 'Patient enrolment is unsatisfactory', 'The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.', '4.6.4', 'Site Discontinuation', 'The Sponsor has the right to close a study site at any time. Reasons for closing a site may', 'include, but are not limited to, the following:', 'Excessively slow recruitment', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '55 / Protocol MO40628, Version 12']['Poor protocol adherence', 'Inaccurate or incomplete data recording', 'Non-compliance with the International Council for Harmonisation (ICH) guideline for', 'Good Clinical Practice', 'No study activity (i.e., all patients have completed the study and all obligations have', 'been fulfilled)', '5.', 'ASSESSMENT OF SAFETY', '5.1', 'SAFETY PLAN', 'Pertuzumab and trastuzumab drug substances in the FDC SC are identical to the drug', 'substances in Perjeta IV, Herceptin IV and Herceptin SC. As described in Section 1.2.4, the', 'safety profiles and tolerability of Herceptin SC and Herceptin IV have been shown to be', 'consistent. As also described in Section 1.2.4, preliminary safety data from healthy', 'volunteers and EBC patients treated with pertuzumab SC co-administered or co-mixed with', 'Herceptin SC are consistent with prior experience with combined treatment with Perjeta IV', 'and Herceptin IV. The safety plans for this study, as well as for the ongoing Phase III Roche', 'Study WO40324 (see Section 1.2.4) comparing pertuzumab and trastuzumab FDC SC with', 'P+H IV, are therefore based on the anticipated safety risks of Herceptin IV and Perjeta IV,', \"alone and in combination, described in the Perjeta and Herceptin Investigator's Brochures.\", 'Measures taken to ensure the safety of patients participating in this study include eligibility', 'criteria designed to exclude patients at higher risk for toxicities and ongoing safety', 'monitoring. Safety monitoring includes assessment of the nature, frequency, and severity of', 'AEs and cardiac function evaluations.', 'The anticipated important safety risks for pertuzumab and trastuzumab are outlined below.', \"Please refer to the Perjeta and Herceptin Investigator's Brochures for complete summaries\", 'of safety information.', '5.1.1', 'Risks Associated with Pertuzumab', '5.1.1.1', 'Hypersensitivity Reactions / Anaphylaxis and Administration-Related', 'Reactions', 'Like other monoclonal antibodies, Perjeta IV has been associated with ARRs. These include:', 'Infusion-related reactions (i.e., a systemic reaction with symptoms such as chills,', 'diarrhoea, fatigue, headache, nausea and pyrexia).', 'Such reactions are likely to be due to cytokine release and typically occur during, or very', 'shortly after, the administration of monoclonal antibodies, but they may also show a', 'delayed onset. In general, infusion-related AEs are more frequent and severe with the', 'first infusion, and decrease in number and severity over time. The majority of AEs', 'resolve fully.', 'Injection-related reactions with SC administration may manifest themselves as:', '-', 'Systemic reactions, similar to the infusion-related reactions', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '56 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}